KOREA
N01
Manufacturer
Drug Formulation (general category), Antisense, RNA, Biopharmaceuticals (general category)
We have 6 pipelines, including 2 clinical-stage and 4 preclinical-stage projects.
□ ATB-301: TGF-β2 targeting ASO anti-cancer new drug used in combination with Interleukin-2
□ ATB-320: Next Generation ASO with enhanced dosing convenience and safety
□ ATB-350: ASO anti-cancer new drug selectively inhibiting KRAS G12V
□ ATB-610: A novel inhalant treatment for IPF with higher selectivity compared to conventional TGF-βR1 (ALK5) inhibitors
□ ATB-330: A small molecule novel compound to treat colorectal cancer
□ ATB-101: World's first fixed dose combination to treat concurrent hypertension and type 2 diabetes